TD Private Client Wealth’s Iovance Biotherapeutics IOVA Stock Holding History

TD Private Client Wealth’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.28K	Hold	309	–	–	﹤0.01%	1436
2026 Q1	$1.08K	Sell	309 -5	-2%	-$16	﹤0.01%	1372
2025 Q4	$857	Buy	+314	New	+$726	﹤0.01%	1397
2022 Q1	–	Sell	-35	Closed	-$668	–	1298
2021 Q4	$668	Sell	35 -96	-73%	-$2.11K	﹤0.01%	1099
2021 Q3	$3.23K	Buy	131 +24	+22%	+$566	﹤0.01%	989
2021 Q2	$2.78K	Buy	107 +48	+81%	+$1.25K	﹤0.01%	1011
2021 Q1	$1.87K	Hold	59	–	–	﹤0.01%	1009
2020 Q4	$2.74K	Buy	59 +25	+74%	+$993	﹤0.01%	933
2020 Q3	$1.12K	Hold	34	–	–	﹤0.01%	954
2020 Q2	$933	Hold	34	–	–	﹤0.01%	969
2020 Q1	$1.02K	Hold	34	–	–	﹤0.01%	932
2019 Q4	$941	Buy	+34	New	+$773	﹤0.01%	952

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

TD Private Client Wealth's IOVA Position: Q2 2026 in Review

TD Private Client Wealth held its Iovance Biotherapeutics (IOVA) position steady in Q2 2026 at 309 shares worth $1.28K. The position accounts for ﹤0.01% of the portfolio, ranked #1436.

TD Private Client Wealth first reported a position in IOVA in Q4 2019 and has held it in 12 quarters since. The position peaked at $3.23K in Q3 2021. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

TD Private Client Wealth held 309 shares of Iovance Biotherapeutics worth $1.28K as of Q2 2026.
TD Private Client Wealth left its Iovance Biotherapeutics share count unchanged in Q2 2026.
Iovance Biotherapeutics made up ﹤0.01% of TD Private Client Wealth's portfolio in Q2 2026, its #1436 holding.
TD Private Client Wealth first reported a position in Iovance Biotherapeutics in Q4 2019 and has held it in 12 quarters since.
TD Private Client Wealth's Iovance Biotherapeutics position peaked at $3.23K in Q3 2021.
292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.